MedTrace Logo

Follow up After Cryoablation of Small Renal Masses.

NCT02411968 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9

Last updated 2019-01-11

No results posted yet for this study

Summary

Currently there is no consensus on post procedural follow up imaging following percutaneous cryoablation of renal tumors. Interpretation of conventional contrast enhanced imaging (CT and MRI) during follow up can be very challenging. The objective of this study is to evaluate the feasibility of early evaluation of the therapeutic effect by performing early follow up imaging after percutaneous MR-guided cryoablation of pT1a renal cell carcinoma using 111In-Girentuximab-DOTA SPECT CT imaging.

Conditions

  • Carcinoma, Renal Cell

Interventions

OTHER

111In-Girentuximab DOTA SPECT

Sponsors & Collaborators

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Jurgen J Futterer, M.D. PhD · Radboud University Medical Center

  • Wim JG Oyen, M.D. PhD · Radboud University Medical Center

  • Peter FA Mulders, M.D. PhD · Radboud University Medical Center

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2018-09-30
Completion
2018-09-30

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02411968 on ClinicalTrials.gov